Compare AEXA & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AEXA | FDMT |
|---|---|---|
| Founded | 2025 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.5M | 504.4M |
| IPO Year | N/A | 2019 |
| Metric | AEXA | FDMT |
|---|---|---|
| Price | $10.86 | $9.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $33.50 |
| AVG Volume (30 Days) | 102.1K | ★ 723.6K |
| Earning Date | 01-01-0001 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $10.49 | $2.24 |
| 52 Week High | $11.91 | $12.34 |
| Indicator | AEXA | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 38.21 | 57.46 |
| Support Level | $10.59 | $8.15 |
| Resistance Level | $11.30 | $9.78 |
| Average True Range (ATR) | 0.22 | 0.62 |
| MACD | -0.02 | 0.14 |
| Stochastic Oscillator | 4.00 | 58.72 |
American Exceptionalism Acquisition Corp A is a blank check company.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.